Abstract
The interaction and possibly interference between viruses infecting a common host population is the problem addressed in this work. We model two viral diseases both of the SIRS type that have similar mechanism of transmission and for which a vaccine exists. The vaccine is characterized by its coverage, induced temporal immunity and efficacy. The population dynamics of both diseases considers infected individuals of each disease and hosts that are susceptible to one but have recovered from the other. We do not incorporate coinfection. We postulate two main transmission factors affecting the effective contact rates: i) that the virus with higher reproduction number can superinfect the one with lower reproduction number and ii) that there is some protection induced by vaccination against the weaker virus that reduces the probability of infection by the stronger virus. Our results indicate that coexistence of the viruses is possible in the long term. The time-dependent effective contact rate may induce either alternating outbreaks of each disease or synchronous outbreaks. We also found the existence of bi-stability triggered by a backward bifurcation, conducive to scenarios where, at the population level, vaccine application may promote persistence of both diseases provided the effective coverage and vaccine efficacy are low.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors acknowledge support from DGAPA-PAPIIT-UNAM grant IV100220 (convocatoria especial COVID-19), JXVH acknowledges support from DGAPA-PAPIIT-UNAM grant IN115720. MAAZ acknowledges support from PRODEP Programme (No. 511-6/2019-8291). MNL acknowledges support from the Asociacion Mexicana de Cultura, A.C.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For this work we do not consider IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos